There have been significant changes in the CLL treatment landscape with the approval of novel targeted therapies and greater understanding of how molecular and mutation status can guide treatment decisions. CARE™ Faculty recently spoke with CLL expert, Dr. Susan O’Brien to get a global perspective on these advances and how they have impacted her practice.
This is the first issue of a CARE™ Global Interview series and covers content on:
- The changing role of chemotherapy in front-line treatment
- Recent practice changing data in the front-line setting
- Considerations for treatment of relapsed/refractory CLL